Lux Research sees an increasingly self-sufficient and self-sustaining biopharma market in China. Business models and value chains are evolving away from low cost manufacturing for export into servicing the China market itself. Evidence of increasing velocity of expansion and acquisition deals are detailed in this report along with increasing innovation and development of local formulation and delivery technology companies within China, some of whom rival their western counterparts in terms of technology sophistication and market reach. This report details comparison of such companies along with notable deals and trends.
Contact us to learn the benefits of becoming a Lux member.
Or call us now
For North America (Boston Headquarters)
+1 (617) 502-5300
For EMEA (Amsterdam)
+31 20 280 7900
For APAC (Singapore)